US judge approves Bayer's Roundup settlement

The settlement aims to resolve nearly all current and future Roundup claims in the US.

US judge approves Bayer's Roundup settlement
Photo: The Guardian

A judge in a state court in St Louis has given final approval to a settlement that Bayer reached with people who say Roundup weedkiller gave them cancer. Judge Timothy Boyer found the deal "fair, reasonable and adequate".

Boyer overruled objections that payouts to individual cancer victims would be too low because earlier claimants who settled were paid more. He also said that delaying payouts could force victims, including those whose cancer is terminal, to wait "an indeterminate number of years" to be paid.

Bayer's chief executive, Bill Anderson, said the approval was a decisive milestone in the company's strategy to mitigate the risks of pending and future Roundup litigation. Bayer bought Monsanto, the maker of Roundup, in 2018 for $63bn, and its share price has fallen 46% since then.

Five months before the latest approval, the US supreme court overturned a $1.25m jury award to John Durnell, ruling 7-2 that a federal pesticide law barred failure-to-warn claims under state law.

The settlement excludes some lawsuits still pending in federal court, and Bayer said about 200 of those cases were still being litigated.

Key facts

  • Judge Timothy Boyer of a state court in St Louis found the settlement "fair, reasonable and adequate".
  • The settlement aims to resolve nearly all current and future Roundup claims in the US.
  • Bayer faced 65,000 claims from people who said they developed cancer after using weedkiller.

Three perspectives

Neutral

A US state court judge has given final approval to Bayer's settlement of Roundup weedkiller cancer claims.

Positive

Bayer's chief executive said the court's final approval is a decisive milestone in the company's strategy to mitigate Roundup litigation risks.

Negative

The judge overruled objections that payouts to individual cancer victims would be too low.

Your week in news, every Wednesday

The biggest stories of the week for your edition, in your inbox every Wednesday morning, your time. Free, and you can unsubscribe at any time.

Choose your news coverage

Please choose and confirm your coverage.

Next storyDaraxonrasib pill makes pancreatic tumours undetectable in one in 12 patients

All sections

Edition